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Worldwide, breast cancer is the most common cancer
aﬀecting women. The disease is more common in the aﬄuent
world, but breast cancer incidence is steadily rising in the
developing world. Breast cancer is a heterogeneous disease
morphologically, immunohistochemically, and also at the
molecular level regardless of the women’s race or geographic
location. Therefore, the prognosis and response to standard
treatments can be highly variable from one patient to
another. The first step towards personalized therapy for
breast cancer is to understand the heterogeneity of the
disease. Pathologists have been aware of breast cancer heterogeneity for a long time and, therefore, devised a grading
system to identify tumors with diﬀerent prognoses. Breast
cancer grading is still very useful clinically (as illustrated in
one of the original manuscripts in this issue by M. Purdom
et al.), but additional prognostic/predictive markers have
further improved our ability to personalize breast cancer
therapy. The division of breast tumors into estrogen receptor
(ER) positive and estrogen receptor-negative groups was
an important step in recognizing heterogeneity and use of
antiestrogen therapy in ER-positive disease is the first example of targeted therapy in human cancers. Recent advances
in gene expression profiling have further exemplified the
heterogeneity of breast cancer. The ER-positive disease is
now split into at least 2 groups, one with good prognosis
(likely luminal A type tumors) and another with poor
prognosis (likely luminal B type tumors). The ER-negative
disease is also split into an HER2-enriched category and
the so-called basal-like breast cancer category. Although the
molecular classes described using gene expression profiling
do have morphologic and immunohistochemical correlates,

there is lack of consensus on a defined morphologic or
immunohistochemical criteria. Nevertheless, the molecular
and subsequent immunohistochemical studies provided a
framework for studying various other parameters or novel
biological markers with respect to the best known prognostic/predictive markers ER, progesterone receptor (PR), and
HER2. Two original articles in this issue have used similar
immunohistochemical definitions to address the issue of
multifocality in breast cancer (T. Tot et al.) and to study
the prevalence of basal-like breast cancer in Sudan (K. D.
Awadelkarim et al.).
The recent advances in breast cancer research has
increased our understanding of breast cancer and provided
us with more refined classifications. However, classifications
do not immediately help breast cancer patients, but the hope
is that understanding the molecular network will pave way
for more targeted treatments. Therefore, studies of novel
breast cancer markers are always useful. One review article
and two original articles addressing these issues are included
in the current issue (review by B. Uziely at al. and original
articles by Y. Y. Wang et al. and by A. Nasir et al.).
In addition to the study of novel markers, traditional
issues related to breast cancer are also discussed in this issue.
Despite the identification of novel markers that provides
insight into breast tumor biology, lymph-node metastasis
still remains one of most important prognostic factor in
breast cancer. V. Van Belle et al. report on the issue of ratio
of positive versus negative lymph nodes by performing a
comparative study of nottingham prognostic index (NPI)
versus log odds prognostic index (Lpi) for short-term breast
cancer-specific disease free survival. Two review articles
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(one by P. Tai et al. and another by G. Peclivanides et al.)
discuss the issues related to sentinel lymph node biopsy and
assessment.
Another common, but important issue in breast cancer
is assessment of HER2 (ERBB2) oncogene. HER2 gene is
amplified/overexpressed in approximately 20% of breast
cancer and is a marker of aggressive disease. However,
with the availability of HER2-targeted therapy, trastuzumab,
the natural history of HER2 disease has been significantly
altered. Trastuzumab treatment is highly eﬀective in HER2
positive tumor, but it is generally ineﬀective in HER2negative disease. Moreover, the treatment is expensive and
potentially cardiotoxic, so patient selection is very important.
Due to the availability of such an eﬀective treatment, it is very
important for pathologists to be aware of all HER2-testing
issues. The article on HER2 testing in breast cancer by S. Shah
and B. Chen provides a comprehensive review on the subject.
Other review articles included in this issue update the
reader on less well-known but increasing-talked-about topics
in recent months, such as angiogenesis in breast cancer (E.
S. Ch’ng et al.), circulating tumor cells in breast cancer (E.
S. Graves et al.), and breast cancer metastasis to the brain
(F. Arshad et al.). Treatment of breast cancer metastasis is
discussed by A. M. Stark.
The scope of breast cancer research is quite broad, and,
is diﬃcult to include all topics in one issue. Nevertheless,
we have tried to include both common and uncommon
topics in a mix of high-quality original and review articles
to satisfy the need of readers with diﬀerent backgrounds. We
hope the readers will find this special issue on breast cancer
stimulating.
Rohit Bhargava
Sunati Sahoo
Nicole Nicosia Esposito
Beiyun Chen
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